Cme Group Inc. · NASDAQ:CME
Cme — Q4 2025 Earnings Presentation
11 slides from Cme's earnings presentation, Feb 4, 2026
Slide 1: 4Q 2025 Earnings Commentary
4Q 2025 Earnings Commentary (unaudited) Notes • All references to “options” or “options contracts” in the text of this document refer to options on futures contracts. “Futures and options” is often simplified to F&O throughout. Short Term Interest Rate products are simplified to STIR and Long Term I
Slide 2: 4Q 2025 Earnings Summary
4Q 2025 Earnings Summary1 CME Group’s strong performance in 4Q25 topped off the best year in the company’s history and the fourth consecutive year of record revenue, as well as operating income, net income Revenue, Adjusted Operating Expense and and diluted EPS on an adjusted basis Adjusted Diluted
Slide 3: Solid, broad-based activity during 2025 and accelerating market data demand contributed to 6% revenue growth
Solid, broad-based activity during 2025 and accelerating market data demand contributed to 6% year-over-year revenue growth CME Group’s highly diverse product set, global distribution, and consistent outreach to market participants through our worldwide salesforce positions the company well througho
Slide 4: Financials ADV Highlights and Longer-Term Trends
4Q 2025 Financials ADV Highlights and Longer-Term Trends Equity Index Treasury F&O ● 4Q25 Financials ADV up 5% from 4Q24 to 21.6 million (millions) Annual ADV (millions) Annual ADV ○ Equity Index ADV up 22% to 7.7 million 7.4 8.3 ○ Treasury F&O ADV of 7.6 million with record Treasury options ADV up
Slide 5: Commodities ADV Highlights and Longer-Term Trends
4Q 2025 Commodities ADV Highlights and Longer-Term Trends Micro Metals ● Higher priced Commodities products driving more of the YoY growth in 4Q25, up Quarterly ADV 1.3M 16% from 4Q24 to 5.8 million, and represented 21% of total volume and 35% of clearing and transaction fee revenue ○ Record quarter
Slide 6: Advancing longer-term innovative initiatives to expand customer base and risk management opportunities
During 4Q25, the company continued to advance several longer-term innovative initiatives related to expanding our customer base and increasing trading and risk management opportunities for market participants Advanced partnership with Announced SEC approval of the Making Cryptocurrency F&O available
Slide 7: New products and services innovation has been a hallmark of CME Group's strategy
New products and services innovation has been a hallmark of CME Group’s strategy Bringing our global participants and next generation traders the necessary tools to effectively manage risk and capture opportunities as markets evolve quickly - more granularity in F&O products provide precision and ac
Slide 8: Strong start to 2026 as market participants continue to turn to CME Group
Strong start to 2026 as market participants continue to turn CME Group Large Open Interest Holders (LOIH) to CME Group as a risk management leader and for unmatched capital efficiencies Aggregate 3,616 CME Group reached all-time record January ADV while OI reached the highest Interest Rates level in
Slide 9: 4Q25 Financial Results
4Q25 Financial Results (millions) Dividends Paid ● 4Q25 revenue was $1.6 billion, up 8% versus ● Adjusted net income was $1.0 billion, compared 4Q24. 4Q25 clearing and transaction fee to $919 million in 4Q24, and adjusted diluted revenue totaled $1.3 billion, including ~$68 earnings per share were $
Slide 10: Financial Results: Appendix – Micro Product Quarterly Details
Financial Results: Appendix – Micro Product Quarterly Details ADV in thousands / RPC in cents Micro Equity Index Products (including Micro Crypto) 4Q23 1Q24 2Q24 3Q24 4Q24 1Q25 2Q25 3Q25 4Q25 ADV 2,250 2,336 2,487 2,945 2,486 3,502 3,607 2,693 3,574 RPC 29.7 30.7 29.9 29.8 31.4 31.0 31.3 31.3 30.2 %
Slide 11: Use of Non-GAAP Measures, Forward-looking Statements, Q&A, Conference Call Details
Use of Non-GAAP Measures A reconciliation of the non-GAAP financial results mentioned to the respective GAAP figures can be found within the Reconciliation of GAAP to non-GAAP Measures chart within the financial statements posted on the Investor Relations page on CME Group’s Web site at www.cmegroup